Zaklad Biologii Molekularnej Wirusow

Gdańsk, Poland

Zaklad Biologii Molekularnej Wirusow

Gdańsk, Poland
SEARCH FILTERS
Time filter
Source Type

Lesiak D.,Zaklad Biologii Molekularnej Wirusow | Brzozowska A.,Zaklad Biologii Molekularnej Wirusow | Bienkowska-Szewczyk K.,Zaklad Biologii Molekularnej Wirusow | Lipinska A.D.,Zaklad Biologii Molekularnej Wirusow
Postepy Mikrobiologii | Year: 2013

Phosphorylation by protein kinases modulates the function of target proteins by interfering with their enzymatic activity, cellular location and/or association with other proteins. Viruses have evolved complex interactions with their hosts and often mimic cellular proteins in order to usurp the cellular machinery for their own benefit, so it is not surprising that vast number of viruses encode protein kinases. Alphaherpesvirus kinase US3 is a conserved multifunctional protein, regulating the egress of viral particles, but also responsible for alterations in cell morphology resulting from the breakdown of actin stress fibers and formation of cell projections. US3 homologs control the trafficking of viral and cellular proteins and inhibit apoptosis. The current review provides an overview of the properties and functions of alphaherpesvirus US3 protein kinase orthologues.


Chmielewska A.M.,Zaklad Biologii Molekularnej Wirusow | Rychlowska M.,Zaklad Biologii Molekularnej Wirusow | Krol E.,Zaklad Szczepionek Rekombinowanych | Solarz K.,Zaklad Biologii Molekularnej Wirusow | Bienkowska-Szewczyk K.,Zaklad Biologii Molekularnej Wirusow
Postepy Higieny i Medycyny Doswiadczalnej | Year: 2015

Despite available treatment, Hepatitis C remains one of most serious burdens to public health. Current therapy based on pegylated interferon-alpha and ribavirin has significant side effects and its effectiveness varies for different genotypes of the virus. Four novel drugs - viral protease inhibitors (telaprevir, boceprevir, simeprevir) and polymerase inhibitor - sofosbuvir have been introduced in last years for use in combination with standard-of-care treatment. For the first time interferon free therapies were approved with the use of combination of sofosbuvi-r+ribavirin. New therapies improve virological response rates but also increase the cost, side effects and raise the issue of drug resistance. Numerous novel anti-HCV compounds have been evaluated in advanced clinical trials including inhibitors of viral proteins (protease, polymerase and NS5A) and inhibitors of host factors involved in HCV replication (cyclophilin A, microRNA - miR-122). New interferon-free therapies reducing severe side effects are expected to enter the market within few months. At the same time eforts are undertaken to determine the host and viral factors with predictive value for HCV treatment response, enabling personalized therapy approach. The main success in this field was the discovery of interleukin IL28B polymorphism, which correlates with positive standard-of-care treatment response. An effective vaccination may be an alternative for antiviral drugs, but no anti-HCV vaccine is available currently. It is well proved that successful vaccination should induce antibody and T-cell responses specific against a range of HCV genotypes. With this aim, new subunit and genetic candidate vaccines have been evaluated in I and II phase clinical trials. This review summarizes the recent developments in the field of new drug development and vaccine studies against hepatitis C virus.


PubMed | Zaklad Biologii Molekularnej Wirusow and Zaklad Szczepionek Rekombinowanych
Type: | Journal: Postepy higieny i medycyny doswiadczalnej (Online) | Year: 2015

Despite available treatment, Hepatitis C remains one of most serious burdens to public health. Current therapy based on pegylated interferon-alpha and ribavirin has significant side effects and its effectiveness varies for different genotypes of the virus. Four novel drugs - viral protease inhibitors (telaprevir, boceprevir, simeprevir) and polymerase inhibitor - sofosbuvir have been introduced in last years for use in combination with standard-of-care treatment. For the first time interferon free therapies were approved with the use of combination of sofosbuvir+ribavirin. New therapies improve virological response rates but also increase the cost, side effects and raise the issue of drug resistance. Numerous novel anti-HCV compounds have been evaluated in advanced clinical trials including inhibitors of viral proteins (protease, polymerase and NS5A) and inhibitors of host factors involved in HCV replication (cyclophilin A, microRNA - miR-122). New interferon-free therapies reducing severe side effects are expected to enter the market within few months. At the same time efforts are undertaken to determine the host and viral factors with predictive value for HCV treatment response, enabling personalized therapy approach. The main success in this field was the discovery of interleukin IL28B polymorphism, which correlates with positive standard-of-care treatment response. An effective vaccination may be an alternative for antiviral drugs, but no anti-HCV vaccine is available currently. It is well proved that successful vaccination should induce antibody and T-cell responses specific against a range of HCV genotypes. With this aim, new subunit and genetic candidate vaccines have been evaluated in I and II phase clinical trials. This review summarizes the recent developments in the field of new drug development and vaccine studies against hepatitis C virus.

Loading Zaklad Biologii Molekularnej Wirusow collaborators
Loading Zaklad Biologii Molekularnej Wirusow collaborators